BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32720700)

  • 1. Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients.
    Rohmer J; Couteau-Chardon A; Trichereau J; Panel K; Gesquiere C; Ben Abdelali R; Bidet A; Bladé JS; Cayuela JM; Cony-Makhoul P; Cottin V; Delabesse E; Ebbo M; Fain O; Flandrin P; Galicier L; Godon C; Grardel N; Guffroy A; Hamidou M; Hunault M; Lengline E; Lhomme F; Lhermitte L; Machelart I; Mauvieux L; Mohr C; Mozicconacci MJ; Naguib D; Nicolini FE; Rey J; Rousselot P; Tavitian S; Terriou L; Lefèvre G; Preudhomme C; Kahn JE; Groh M;
    Am J Hematol; 2020 Nov; 95(11):1314-1323. PubMed ID: 32720700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.
    Pardanani A; Lasho T; Barraco D; Patnaik M; Elala Y; Tefferi A
    Am J Hematol; 2016 Mar; 91(3):E10-1. PubMed ID: 26663400
    [No Abstract]   [Full Text] [Related]  

  • 3. Imatinib for the treatment of hypereosinophilic syndromes.
    Helbig G
    Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
    Rathe M; Kristensen TK; Møller MB; Carlsen NL
    Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete response of myeloid sarcoma with FIP1L1-PDGFRA -associated myeloproliferative neoplasms to imatinib mesylate monotherapy.
    Tang TC; Chang H; Chuang WY
    Acta Haematol; 2012; 128(2):83-7. PubMed ID: 22722648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
    Metzgeroth G; Walz C; Score J; Siebert R; Schnittger S; Haferlach C; Popp H; Haferlach T; Erben P; Mix J; Müller MC; Beneke H; Müller L; Del Valle F; Aulitzky WE; Wittkowsky G; Schmitz N; Schulte C; Müller-Hermelink K; Hodges E; Whittaker SJ; Diecker F; Döhner H; Schuld P; Hehlmann R; Hochhaus A; Cross NC; Reiter A
    Leukemia; 2007 Jun; 21(6):1183-8. PubMed ID: 17377585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
    Miyazawa K; Kakazu N; Ohyashiki K
    Int J Hematol; 2007 Jan; 85(1):5-10. PubMed ID: 17261495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.
    Pardanani A; Ketterling RP; Li CY; Patnaik MM; Wolanskyj AP; Elliott MA; Camoriano JK; Butterfield JH; Dewald GW; Tefferi A
    Leuk Res; 2006 Aug; 30(8):965-70. PubMed ID: 16406016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement.
    Coltro G; Santi R
    Blood; 2023 May; 141(20):2541. PubMed ID: 37200055
    [No Abstract]   [Full Text] [Related]  

  • 10. [Myeloproliferative hypereosinophilic syndrome revealed by bipolar mucosal ulcerations].
    Isvy-Joubert A; Hickman G; Flageul B; Battistella M; Bagot M; Galicier L; Petit A
    Ann Dermatol Venereol; 2012 Oct; 139(10):636-40. PubMed ID: 23122377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia.
    Wang J; Zhang Q; Zeng H; Chen B; Ouyang J
    Pharmacogenomics; 2016; 17(2):99-102. PubMed ID: 26666578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FIP1L1-PDGFRA fusion gene in T-lymphoblastic lymphoma: A case report.
    Ali S; Al-Qattan Y; Awny W; Hamadah A; Pinto K; AlShemmari S
    Cancer Rep (Hoboken); 2023 Jan; 6(1):e1769. PubMed ID: 36517458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.
    Helbig G; Kyrcz-Krzemien S
    Leuk Lymphoma; 2013 Apr; 54(4):897-8. PubMed ID: 23025324
    [No Abstract]   [Full Text] [Related]  

  • 14. Atypical Phenotype and Treatment Response Pattern in a Patient with FIP1L1-PDGFRα Mutation.
    Bikhchandani M; Johnson R; Tuan B; Tefferi A
    Acta Haematol; 2018; 140(2):67-70. PubMed ID: 30184522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The efficacy of imatinib mesylate for patients with myeloproliferative neoplasm (MPN) with eosinophilia].
    Zhang Y; Qin TJ; Zhou CL; Liu L; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jun; 30(6):381-4. PubMed ID: 19951530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.
    Barraco D; Carobolante F; Candoni A; Simeone E; Piccaluga P; Tabanelli V; Fanin R
    Eur J Haematol; 2014 Jun; 92(6):541-5. PubMed ID: 24460680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation.
    Metzgeroth G; Schwaab J; Naumann N; Jawhar M; Haferlach T; Fabarius A; Hochhaus A; Hofmann WK; Cross NCP; Reiter A
    Blood Adv; 2020 Feb; 4(3):440-443. PubMed ID: 31995156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up.
    Srinivasan A; Scordino T; Baker A
    J Pediatr Hematol Oncol; 2019 May; 41(4):334-335. PubMed ID: 30807397
    [No Abstract]   [Full Text] [Related]  

  • 19. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia.
    von Bubnoff N; Sandherr M; Schlimok G; Andreesen R; Peschel C; Duyster J
    Leukemia; 2005 Feb; 19(2):286-7. PubMed ID: 15618966
    [No Abstract]   [Full Text] [Related]  

  • 20. Myocarditis, kidney injury, and hypereosinophilia: FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasm with eosinophilia.
    Reid SE; Patel SA
    Blood; 2021 Sep; 138(12):1086. PubMed ID: 34554219
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.